Efficacy and Hematologic Toxicity of Salvage Chemotherapy Following Stem Cell-Supported High-Dose Chemotherapy in Women with Recurrent Ovarian Cancer

By Cook S.   Penson R.   Duska L.   Nikrui N.   Goodman A.   Fuller A.   Seiden M.  

Gynecologic Oncology, Vol. 77, Iss. 1, 2000-04 ,pp. : 48-54

Elsevier

Access to resources Recommend Favorite

Cycles of Dose-Intensive Chemotherapy with Peripheral Stem Cell Support in Persistent or Recurrent Platinum-Sensitive Ovarian Cancer

By Morgan M.A.   Stadtmauer E.A.   Luger S.M.   Porter D.L.   Mangan P.A.   O'neil P.   Kamelle S.   Benjamin I.   Mick R.   King S.A.   Rubin S.C.  

Gynecologic Oncology, Vol. 67, Iss. 3, 1997-12 ,pp. : 272-276

Elsevier

Access to resources Recommend Favorite

The changing landscape of therapeutic strategies for recurrent ovarian cancer

By Baumann Klaus H   Wagner Uwe   du Bois Andreas  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1135-1147

Future Medicine

Access to resources Recommend Favorite

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

By Hasenburg A.   Tong X.-W.   Fischer P.D.   Rojas-Martinez A.   Nyberg-Hoffman C.   Kaplan A.L.   Kaufman R.H.   Ramzy I.   Aguilar-Cordova E.   Kieback D.G.  

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 549-554

Elsevier

Access to resources Recommend Favorite

A Phase I/II Study of Topotecan in Combination with Carboplatin in Recurrent Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Sciatta C.   Polverino G.P.   Rosa C.   Guarnerio P.   Parazzini F.  

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 477-480

Elsevier

Access to resources Recommend Favorite